Patents by Inventor Nurit Livnah
Nurit Livnah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9943489Abstract: The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 3, 2011Date of Patent: April 17, 2018Assignee: PHARMATWOB LTD.Inventors: Yoram Sela, Nurit Livnah, Itschak Lamensdorf, Tomer Madmon
-
Patent number: 9504657Abstract: A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline.Type: GrantFiled: June 29, 2015Date of Patent: November 29, 2016Assignee: PHARMATWOB LTD.Inventors: Nurit Livnah, Pninit Litman, Sarit Zaksh
-
Publication number: 20150297530Abstract: A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline.Type: ApplicationFiled: June 29, 2015Publication date: October 22, 2015Inventors: Nurit LIVNAH, Pninit LITMAN, Sarit ZAKSH
-
Publication number: 20150079187Abstract: A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline.Type: ApplicationFiled: January 10, 2013Publication date: March 19, 2015Inventors: Nurit Livnah, Pninit Litman, Sarit Zaksh
-
Publication number: 20120301542Abstract: The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 3, 2011Publication date: November 29, 2012Applicant: Pharma Two B Ltd.Inventors: Yoram Sela, Nurit Livnah, Itschak Lamensdorf, Tomer Madmon
-
Patent number: 8283355Abstract: Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders.Type: GrantFiled: November 7, 2007Date of Patent: October 9, 2012Assignee: Proteologics, Ltd.Inventors: Philippe Nakache, Itzchak Angel, Nurit Livnah, Maxim Borovitov
-
Publication number: 20120015967Abstract: Pyridine and pyrimidine derivatives inhibit ubiquitination of human polypeptides, particularly of POSH and POSH-associated proteins such as HERPUD1, and can be used as medicaments for treatment of viral infections caused by virus such as HIV and for treatment of neurological disorders or diseases.Type: ApplicationFiled: August 21, 2008Publication date: January 19, 2012Applicant: PROTEOLOGICS, LTD.Inventors: Philippe Nakache, Nurit Livnah
-
Publication number: 20100179178Abstract: Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders.Type: ApplicationFiled: November 7, 2007Publication date: July 15, 2010Applicant: Proteologics LtdInventors: Philippe Nakache, Itzchak Angel, Nurit Livnah, Maxim Borovitov
-
Patent number: 7700717Abstract: Novel photo-active labeled diagnostic and therapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the photo-active backbone cyclized somatostatin analogs, reagents for synthesizing same, and methods of using such compositions for diagnostic and therapeutic purposes including optical imaging and photodynamic therapy are also disclosed.Type: GrantFiled: September 24, 2004Date of Patent: April 20, 2010Assignee: DeveloGen Israel Ltd.Inventors: Thomas A. Bonasera, Nurit Livnah, Yoseph Salitra, Tamar Yechezkel
-
Patent number: 7407939Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: GrantFiled: January 23, 2004Date of Patent: August 5, 2008Assignee: CureGenics Ltd.Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen, Pninit Litman, Hanoch Senderowitz
-
Publication number: 20080070843Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: ApplicationFiled: September 27, 2007Publication date: March 20, 2008Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen
-
Publication number: 20070078092Abstract: The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.Type: ApplicationFiled: December 6, 2005Publication date: April 5, 2007Inventors: Nurit Livnah, Alexander Levitzki, Hanoch Senderovitz, Tamar Yechezkel, Yosef Salitra, Pninit Litman, Osnat Ohne
-
Patent number: 6949565Abstract: Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.Type: GrantFiled: May 30, 2001Date of Patent: September 27, 2005Assignees: Develogen Israel Ltd., Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Nurit Livnah, Alexander Levitzki, Hadas Reuveni
-
Publication number: 20050090429Abstract: Novel photo-active labeled diagnostic and therapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the photo-active backbone cyclized somatostatin analogs, reagents for synthesizing same, and methods of using such compositions for diagnostic and therapeutic purposes including optical imaging and photodynamic therapy are also disclosed.Type: ApplicationFiled: September 24, 2004Publication date: April 28, 2005Inventors: Thomas Bonasera, Nurit Livnah, Yoseph Salitra, Tamar Yechezkel
-
Publication number: 20050026840Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: ApplicationFiled: January 23, 2004Publication date: February 3, 2005Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen, Pninit Litman, Hanoch Senderowitz
-
Publication number: 20040102364Abstract: Novel radiodiagnostic and radiotherapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the backbone cyclized somatostatin analogs and radiolabelled analogs, reagents for synthesizing same, and methods of using such compositions for radiodiagnostic and radiotherapeutic purposes are also disclosed.Type: ApplicationFiled: August 4, 2003Publication date: May 27, 2004Inventors: Thomas A. Bonasera, Nurit Livnah, Tamar Yechezkel, Yoseph Salitra
-
Publication number: 20040019077Abstract: Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.Type: ApplicationFiled: April 3, 2003Publication date: January 29, 2004Inventors: Nurit Livnah, Alexander Levitzki, Hadas Reuveni